ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023

Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).

Valentina D Gusarova et al.PubMed ↗Publisher ↗

No numbers read from the abstract.